BioWorld MedTech

June 3, 2016

View Archived Issues

China Resources exits med-tech space to focus on other health care areas

FDA clarifies how IDE categories work as they relate to Medicare coverage

Financings

Appointments & Advancements

Other news to note

Product briefs

Keeping you up to date on recent developments with diagnostics

FDA approves first liquid biopsy test to aid clinical decisions based on EGFR mutation

Roche Holding AG, of Basel, Switzerland, is the first company with an FDA-approved, blood-based genetic test to detect a gene mutation associated with the most common type of lung cancer. Read More

France's AAA gets FDA win for Netspot to locate rare tumors

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Science in 2025: the best of the rest

BioWorld Science

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...